Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Annual General Meeting will take place on 8 May 2024 at the Congress Center in Basel, Switzerland Albert M. Baehny will…
Annual General Meeting will take place on 8 May 2024 at the Congress Center in Basel, Switzerland Albert M. Baehny will…
Wolfgang Wienand, currently CEO of Swiss CDMO Siegfried Holding AG, will become Chief Executive Officer of Lonza in the…
Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 b…
Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CH…
At its Capital Markets Day, Lonza outlined its Mid-Term Guidance for 2024 to 2028, including: 11–13% sales growth, 3…
The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercia…
Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of…
Capital Markets Day 2023 will be hosted by members of the Lonza Executive Committee The presentation will provide an ove…
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition w…
Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing…